Browse > Article
http://dx.doi.org/10.14480/JM.2014.12.2.77

A comprehensive review of the therapeutic effects of Hericium erinaceus in neurodegenerative disease  

Kim, Young Ock (Herbal Crop Utilization Research Team, Department of Medicinal Crop Research, National Institute of Horticultural & Herbal Science, Rural Development Administration)
Lee, Sang Won (Herbal Crop Utilization Research Team, Department of Medicinal Crop Research, National Institute of Horticultural & Herbal Science, Rural Development Administration)
Kim, Jin Seong (Herbal Crop Utilization Research Team, Department of Medicinal Crop Research, National Institute of Horticultural & Herbal Science, Rural Development Administration)
Publication Information
Journal of Mushroom / v.12, no.2, 2014 , pp. 77-81 More about this Journal
Abstract
Mushrooms are considered not only as food but also for source of physiologically beneficial medicines. The culinary-medicinal mushrooms may important role in the prevention of age-associated neurological dysfunctions, including Alzheimer's and Parkinson's diseases. Hericium erinaceus (H. erinaceus), is edible mushrooms, is a parasitic fungus that grows hanging off of logs and trees and well established candidate for brain and nerve health. H. erinaceus contains high amounts of antioxidants, beta-glucan, polysaccharides and a potent catalyst for brain tissue regeneration and helps to improve memory and cognitive functions. Its fruiting bodies and the fungal mycelia exhibit various pharmacological activities, including the enhancement of the immune system, antitumor, hypoglycemic and anti-aging properties. H. erinaceus stimulates the synthesis of Nerve Growth Factor (NGF) which is the primary protein nutrient responsible for enhancing and repairing neurological disorders. Especially hericenones and erinacines isolated from its fruitin body stimulate NGF, synthesis. This fungus is also utilized to regulate blood levels of glucose, triglycerides and cholesterol. H. erinaceus can be considered as useful therapeutic agents in the management and/or treatment of neurodegeneration diseases. However, this review focuses on in vitro, in vivo and clinical trials for neurodegerative disease.
Keywords
Hericium erinaceus; Nerve growth factor; Neurodegenerative disease; Blood-brain barrier;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Chang ST, Buswell JA. 2008. Development of the world mushroom industry: Applied mushroom biology and international mushroom organizations. Int J Med Mushrooms. 10:195-208.   DOI
2 Kawagishi H, Ando M, Mizuno T. 1990. Hericenone A and B as cytotoxic principles from the mushroom Hericium erinaceum. Tetrahedron Lett. 31:373-376.   DOI   ScienceOn
3 Kawagishi H, Ando M, Sakamoto H. 1991. Hericenone C, D and E, stimulators of nerve growth factor (NGF) synthesis, from the mushroom Hericium erinaceum. Tetrahedron Lett. 32:4561-4564.   DOI   ScienceOn
4 Yang BK, Park JB, Song CH. 2003. Hypolipidemic effect of an Exo-biopolymer produced from a submerged mycelial culture of Hericium erinaceus. Biosci Biotechnol Biochem. 67:1292-1298.   DOI   ScienceOn
5 Saito T, Aoki F, Hirai H, Inagaki T, Matsunaga Y, Sakakibara T, Sakemi S, Suzuki Y, Watanabe S, Suga O, Sujaku T, Smogowicz AA, Truesdell SJ, Wong JW, Nagahisa A, Kojima Y, Kojima N. 1998. Erinacine E as a kappa opioid receptor agonist and its new analogs from a basidiomycete, Hericium ramosum. J Antibiot (Tokyo). 51:983-990.   DOI
6 Stamets P. 2005. Notes on nutritional properties of culinary-medicinal mushrooms. Int J Med Mushrooms. 7:109-116.
7 Stein C, Millan M J, Shippenberg T S, Peter K, Herz A. 1989. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. Pharmacol Exp Ther. 248:1269-1275.
8 Tuszynski MH, U HS, Amaral DG, Gage FH. 1990. Nerve growth factor infusion in the primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neurosci. 10:3604-36014.
9 Watanabe H, Takano M, Umino A, Ito T, Ishikawa H, and Nakada M. 2007. Enantioselective total synthesis of (-)-erinacine B. Org Lett. 18:359-362.
10 Wong KH, Sabaratnam V, and Abdullah N. 2007. Activity of aqueous extracts of Lion's Mane Mushroom Hericium erinaceus (Bull.: Fr.) Pers. (Aphyllophoromycetideae) on the neural cell line NG108-15. Int J Med Mushrooms. 9:57-65.   DOI
11 Kawagishi H, Ando M, Shinba K. 1993. Chromans, hericenone F, G and H from the mushroom Hericium erinaceum. Phytochemistry. 32:175-178.
12 Kawagishi H, Shimada A, Shirai R. 1994. Erinacines A, B and C, strong stimulators of nerve growth factor (NGF)-synthesis, from the mycelia of Hericium erinaceum. Tetrahedron Lett. 35:1569-1572.   DOI   ScienceOn
13 Capsoni S, Giannotta S, Cattaneo A. 2002. Nerve growth factor and galatamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci USA. 99:12423-12437.
14 Kenmoku H, Shimai T, Toyomasu T, Kato N, Sassa T, Erinacine Q. 2002. A new erinacine from Hericium erinaceum, and its biosynthetic route to erinacine C in the basidiomycete. Biosci Biotechnol Biochem. 66:571-575.   DOI   ScienceOn
15 Mattson MP. 1997. Neuroprotective signal transduction: relevance to stroke. Neurosci Biobehav Rev. 21:193-206.   DOI   ScienceOn
16 Mori K, Obara Y, Hirota M, Azumi Y, Kinugasa S, Inatomi S, Nakahata N. 2008. Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. Biol Pharm Bull. 31:1727-1732.   DOI   ScienceOn
17 Park YS, Lee HS, Won MH, Lee JH, Lee SY, Lee HY. 2002. Effect of an exo-polysaccharide from the culture broth of hericium erinaceus on enhancement of growth and differentiation of rat adrenal nerve cells. Cytotechnology. 39:155-162.   DOI   ScienceOn
18 Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. 2009. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 23:367-372.   DOI   ScienceOn
19 Nagano M, Shimizu K, Kondo R, Hayashi C, Sato D, Kitagawa K, Ohnuki K. 2010. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomed Res. 31:231-237.   DOI
20 Obara Y, Nakahata N. 2002. The signaling pathway of neurotropic factor. Drug News and Perspect. 15:290-298.   DOI   ScienceOn
21 Yamada K, Nitta A, Hasegawa T, Fuji K, Hiramatsu M, Kameyama T, Furukawa Y, Hayashi K, Nabeshima T. 1997. Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease. Behav Brain Res. 83:117-122.   DOI   ScienceOn